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Abstract
Background: The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine
therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely
addressed.
Methods: Postmenopausal women with untreated stage I–III HR+/HER2-negative breast cancer were randomized (1:1:1)
to receive 3 weeks of letrozole (LTZ) 2.5mg/day, oral mVNB 50mg 3 days/week, or the combination. The primary
objective was to evaluate, within PAM50 Luminal A/B disease, if the anti-proliferative effect of LTZ+mVNB was superior to
monotherapy. An anti-proliferative effect was defined as the mean relative decrease of the PAM50 11-gene proliferation
score in combination arm vs. both monotherapy arms. Secondary objectives included the evaluation of a comprehensive
panel of breast cancer-related genes and safety. An unplanned analysis of stromal tumor-infiltrating lymphocytes (sTILs)
was also performed. PAM50 analyses were performed using the nCounter®-based Breast Cancer 360™ gene panel, which
includes 752 genes and 32 signatures.
Results: Sixty-one patients were randomized, and 54 paired samples (89%) were analyzed. The main patient characteristics
were mean age of 67, mean tumor size of 1.7 cm, mean Ki67 of 14.3%, stage I (55.7%), and grades 1–2 (90%). Most baseline
samples were PAM50 Luminal A (74.1%) or B (22.2%). The anti-proliferative effect of 3weeks of LTZ+mVNB (− 73.2%) was
superior to both monotherapy arms combined (− 49.9%; p= 0.001) and mVNB (− 19.1%; p< 0.001). The anti-proliferative
effect of LTZ+mVNB (− 73.2%) was numerically higher compared to LTZ (− 65.7%) but did not reach statistical significance
(p= 0.328). LTZ+mVNB induced high expression of immune-related genes and gene signatures, including CD8 T cell
signature and PDL1 gene and low expression of ER-regulated genes (e.g., progesterone receptor) and cell cycle-related and
DNA repair genes. In tumors with ≤ 10% sTILs at baseline, a statistically significant increase in sTILs was observed following
LTZ (paired analysis p= 0.049) and LTZ+mVNB (p= 0.012). Grade 3 adverse events occurred in 3.4% of the cases.
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Conclusions: Short-term mVNB is well-tolerated and presents anti-proliferative activity alone and in combination with LTZ.
The high expression of immune-related biological processes and sTILs observed with the combination opens the possibility
of studying this combination with immunotherapy. Further investigation comparing these biological results with other
metronomic schedules or drug combinations is warranted.
Trial registration: NCT02802748, registered 16 June 2016.
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Background
In hormone receptor-positive and HER2-negative
(HR+/HER2−) early breast cancer, adjuvant endocrine
therapy for 5–10 years is recommended for all patients
whereas multi-agent chemotherapy (mostly anthracy-
cline/taxane-based) is recommended for patients with
high-risk tumors [1]. However, despite treatment with
adjuvant endocrine and multi-agent chemotherapy,
patients with high-risk HR+/HER2− disease still have
a substantial risk of relapsing [2–5]. A similar si-
tuation exists in advanced/metastatic HR+/HER2− dis-
ease, where the median overall survival does not
exceed 30–35 months [6, 7]. Although recent random-
ized studies based on two different treatment stra-
tegies targeting the cell cycle showed exciting results
[8–13], new therapies or treatment approaches are
needed in order to improve the outcomes in HR+/
HER2− disease.
Clinical development of metronomic therapy alone or in
combination therapy has been scarce. Regarding breast
cancer, different chemotherapy agents currently used have
been evaluated within metronomic regimens, often com-
bined with hormonal therapy, targeted agents such as tras-
tuzumab or bevacizumab, or vaccines. Vinca alkaloids
such as vinorelbine act mainly as mitotic spindle poisons
which impair chromosomal segregation during mitosis
[14, 15]. In common with other agents in this class, vino-
relbine (25–30mg/m2 iv on days 1 and 8 every 3 weeks)
blocks cells at G2/M when present at concentrations close
to the IC50 [14]. In a Luminal/HER2-negative breast
cancer model (i.e., MCF7), vinorelbine at 2 nM induced
apparent G1-phase accumulation as well as the induction
of CDK inhibitor p21(WAF1/CIP1) protein and the
dephosphorylated form of retinoblastoma protein [16]. In
breast cancer, a wide range of phase II and III studies have
now established the activity of vinorelbine alone, or in
combination with other chemotherapeutic agents, in the
treatment of early and advanced breast cancer [17]. More
recently, studies have confirmed that metronomic oral
vinorelbine can safely be administered at doses up to 50
mg three times a week [18, 19]. This strategy might not
only affect the cell cycle but also target tumor angiogen-
esis and the immune system [20, 21].
Clinical trials in the preoperative setting collecting
samples after 2 weeks of treatment have demonstrated
the clinical validity of Ki67 as a predictor of benefit from
endocrine treatment as well as a predictor of long-term
survival outcome [22]. Therefore, a short-term non-
therapeutic “window” studies might offer a clinical plat-
form for rapid, efficient testing of anticancer agents and
new combinations in breast cancer. Designed as a “win-
dow of opportunity” study, here we present the results
of the SOLTI-1501 VENTANA trial, aiming to evaluate
the anti-proliferative effect of oral metronomic vinorel-
bine (mVNB) alone or in combination with endocrine
therapy in patients with untreated HR+/HER2− breast
cancer.
Methods
Study design and participants
The VENTANA is a multicenter, window of opportun-
ity, three-arm, randomized trial across ten hospitals in
Spain. Female patients aged at least 18 years and post-
menopausal were eligible if they had previously un-
treated, histologically confirmed stage I–IIIA invasive
breast cancer, with primary tumors larger than 1 cm in
diameter (as measured by ultrasound or MRI), clinical
nodal status of 0–1, and HR-positive and HER2-nega-
tive according to ASCO/CAP guidelines [23, 24]. Pa-
tients also had to have an Eastern Cooperative
Oncology Group (ECOG) performance status of 0–2
and adequate hematological counts and hepatic and
renal function. Patients were excluded if they had mul-
ticentric tumors and received prior anti-cancer therapy.
Detailed inclusion and exclusion criteria can be found
in www.clinicaltrials.gov.
All patients provided written informed consent, and
the protocol was approved by the Ethics Committees
from all participating institutions and Spanish Health
Authorities. The study was conducted in accordance
with Good Clinical Practice principles, the Declaration
of Helsinki, and all local regulations.
Procedures
Patients were randomized (1:1:1) to receive letrozole
(LTZ) 2.5 mg daily, oral mVNB 50mg 3 days a week, or
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LTZ 2.5 mg daily and mVNB 50mg three times a week
during 3 weeks. Any adverse event and relationship to
study medication were recorded and graded according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0. After 3 weeks of
treatment, patients underwent a surgery. Tumor samples
were collected in less than 28 days before the therapy
and after 3 weeks of treatment (within 5 days after the
last dose). Following surgery, adjuvant treatment was as
per investigator’s choice and local standards of care out-
side the scope of this protocol.
Outcomes
Primary objective assessed if oral mVNB in combination
with LTZ induce a superior anti-proliferative effect than
either drug alone in patients with early breast cancer de-
fined as luminal by PAM50. Proliferation was evaluated
by measuring the mean expression of 11 proliferative-re-
lated genes contained in the PAM50 assay as previously
described [25].
Secondary objectives included the assessment of the
anti-proliferative of mVNB alone or in combination with
endocrine therapy in patients with PAM50 Luminal A
and Luminal B breast cancer. An unplanned analysis of
stromal tumor-infiltrating lymphocytes (sTILs) and
safety of the treatments was also analyzed.
Gene expression analysis
A section of the formalin-fixed paraffin-embedded (FFPE)
breast tissue was examined with hematoxylin and eosin
staining to confirm the presence of invasive tumor cells and
to determine the minimum tumor surface area. At least two
10-μm FFPE slides were used to purify total RNA using the
High Pure FFPET RNA Isolation Kit (Roche, Indianapolis,
IN, USA). Macrodissection was performed in baseline sam-
ples (when needed) to avoid contamination with normal
breast tissue. A minimum of ~ 100 ng of total RNA was used
to measure the expression of 752 breast cancer-related genes
setting up the Breast 360™ Codeset using the nCounter plat-
form (Nanostring Technologies, Seattle, WA, USA), which
includes the 50 genes of the PAM50 subtype predictor and
702 additional genes that encompass 32 gene expression sig-
natures (Additional file 1: Table S1). Data was normalized
using 5 housekeeping genes and log2 transformed. Intrinsic
molecular subtypes were identified using the research-based
PAM50 predictor as previously described [26].
Stromal tumor-infiltrating lymphocytes
sTIL determination was obtained from central review
blinded from clinical-pathological and outcome data.
Histopathological analysis of the proportion of sTILs
was done in whole sections of tumor tissue stained with
hematoxylin and eosin (H&E). sTILs were quantified
according to the 2014 Guidelines developed by the Inter-
national TILs Working Group [27].
Ki67
Ki67 immunohistochemistry data was obtained from
central review blinded from clinical-pathological and
outcome data. Ki67 was assessed by immunohistochem-
istry using anti-Ki67 (30-9) rabbit monoclonal primary
antibody (Ventana Medical System). In all samples, Ki67
interpretation criteria were done according to the latest
international recommendations [28].
Statistical analysis
This study is exploratory. The sample size chosen was
not based on a formal statistical assumption since no
prior window study has evaluated this combination
and this biomarker (i.e., 11-gene proliferation signa-
ture). For the primary endpoint, the 11-gene prolifera-
tion score was used, which is calculated by obtaining
the mean expression of 11 proliferation-related genes
of the PAM50 assay (BIRC5, CCNB1, CDC20, CDCA1,
CEP55, KNTC2, MKI67, PTTG1, RRM2, TYMS and
UBE2C). All analyses regarding the proliferation score
changes were performed on a per-protocol population,
defined as all patients who completed 3 weeks of treat-
ment and for whom tumor biopsy specimens were
available for assessment of biologic response.
The association between two variables was evaluated
using Student’s t test, Pearson’s χ2 test, or Fisher’s exact
test. All statistical tests were two-sided and considered
significant when P ≤ 0.05. To identify genes differentially
expressed between paired baseline and surgical samples,
a paired two-class significance analysis of microarrays
(SAM) was used with a false discovery rate (FDR) ≤ 5%.
All statistical analyses were performed using the R v3.2.3
software.
Results
Clinical-pathological characteristics
From July 2016 to January 2018, 61 patients with newly di-
agnosed and untreated HR+/HER2− breast cancer were
randomized across 10 centers in Spain. Patient characteris-
tics are summarized in Table 1. Patients and tumor charac-
teristics were balanced between the treatment groups. At
baseline, the mean tumor size was 1.7 cm (range 0.8–3.5)
and mean Ki67 was 14.3% (range 1–50%). Clinical stage I
disease represented 55.7% (n = 34), and most patients had
clinically node-negative (n = 58; 95.1%) and grade 1–2
(90%) disease. Finally, 4 patients withdrew consent, and the
vast majority of patients (n = 57; 93.4%) completed the
treatment as planned. Samples were obtained from 57
patients. Fifty-four paired samples (89%) were analyzed and
reported here (Fig. 1).
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Intrinsic subtype
At baseline, the distribution of the PAM50 intrinsic sub-
types was as follows: Luminal A (n = 40, 74.1%), Luminal
B (n = 12, 22.2%), HER2-enriched (n = 1, 1.9%), and Nor-
mal-like (n = 1, 1.9%). At surgery, the distribution of the
PAM50 intrinsic subtypes was as follows: Luminal A
(n = 46, 85.2%), Luminal B (n = 2, 3.7%), and Normal-like
(n = 6, 11.1%). A significant decrease of Luminal B
disease was observed at surgery compared to baseline
(22.2% vs. 3.7%; p = 0.004). At baseline, Luminal A and
Luminal B were identified in all arms (Fig. 2a, c, e), the
only patient with HER2-enriched disease was identified
in the combination arm (Fig. 2e). At surgery, Luminal B
was identified only in the mVNB monotherapy arm
(Fig. 2d). No statistically significant differences in intrin-
sic subtype were observed between baseline and surgery
across the treatment arms (Fig. 2).
Changes in the 11-gene proliferation score
The 11-gene proliferative score in the baseline tumor sam-
ples was significantly higher than surgical samples (52.6
vs. 27.5; p < 0.0001) (Fig. 3a). Regarding the primary ob-
jective of the study, the anti-proliferative effect arm in lu-
minal tumors of the combination of mVNB and LTZ was
superior to both monotherapy arms combined (− 73.2%
[95% IC − 82.9 to − 58.3%] vs. − 49.9% [95% IC − 61.3 to
− 35.1%]; p = 0.001) (Fig. 3c). The anti-proliferative effect
in the different arm in luminal tumors was as follows: in
LTZ+mVNB arm, − 73.2% (95% IC − 82.9 to − 58.3%); in
LTZ arm, − 65.7% (95% IC − 75.3 to − 52.5%); and in
mVNB arm, − 19.1% (95% IC − 39.4 to 7.8%).
As a secondary objective, we compared the anti-prolifera-
tive effect between each treatment arm (Fig. 3c) and ob-
served that both LTZ-containing arms showed a superior
anti-proliferative effect compared to mVNB monotherapy
(− 19.1%; p < 0.0001). No statistically significant difference
was observed between the combination arm and LTZ-only
arm (− 73.2% vs. − 65.7%; p = 0.328).
The correlation coefficient (r) between the 11-gene
proliferation score and Ki67 by immunohistochemistry
was strong (r = 0.76) (Additional file 2: Figure S1).
Overall, a significant and profound decrease in the 11-
gene proliferation score was observed in both LTZ
arms (Fig. 3b). In the mVNB monotherapy arm, most
tumors (73.3%) showed a decrease in proliferation (blue
lines); however, this decrease was statistically non-sig-
nificant; in addition, 4 of 15 patients showed an in-
crease in proliferation in the mVNB monotherapy arm.
Treatment safety
The most frequent adverse events were arthralgias, as-
thenia, diarrhea, hot flushes, and nausea and occurred
Table 1 Patient demographics at baseline
All patients, N = 61 Patients with paired tumor
samples, N = 54
Mean age (range) 67 [53–86] 67 [53–86]
Tumor size (mean, range) 1.7 [0.8–3.5] 1.7 [0.8–3]
Clinical tumor stage
T1 34 (55.7%) 30 (55.6%)
T2 27 (44.3%) 24 (44.4%)
Clinical lymph nodal status
N0 58 (95.1%) 53 (98.1%)
N1 3 (4.9%) 1 (1.9%)
Histological grade
G1 23 (37.7%) 21 (38.9%)
G2 32 (52.4%) 29 (53.7%)
G3 2 (3.3%) 2 (3.7%)
NA 4 (6.6%) 2 (3.7%)
ECOG
0 54 (88.5%) 47 (87.0%)
1 7 (11.5%) 7 (13.0%)
Arms
Letrozole 21 (34.4%) 20 (37.0%)
mVNB 20 (32.8%) 15 (27.8%)
Letrozole+mVNB 20 (32.8%) 19 (35.2%)
NA not available; mVNB metronomic vinorelbine
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in < 10% of the cases (Additional file 5: Table S2). Two
cases (3.4%) of grade 3 adverse event, both in the
mVNB-only arm, were observed after completing the
3-week treatment. One case was an acute pancreatitis
in a patient with a history of cholelithiasis. The other
case was an acute gastroenteritis. Overall, there were
no discontinuations due to toxicity.
Changes in selected genes and gene signatures
To further identify the biological changes induced by
each treatment, we explored the expression at week 3
compared to baseline of 49 selected genes and gene
signatures tracking various biological processes such as
estrogen-regulated genes, PAM50 risk of relapse (ROR)
score, hypoxia, immune infiltration, ERBB2, estrogen
receptor (i.e., ESR1), or immune checkpoint inhibitor
PDL1 (Figs. 4 and 5a, b).
As expected, the expression of many other biological pro-
cesses beyond proliferation changed during treatment. For
example, both LTZ-containing arms induced a strong
decrease of PAM50 ROR score, Luminal B signature, and
ER-regulated genes, including ESR1 and progesterone recep-
tor (PGR). On the contrary, both LTZ-containing arms, and
specially the LTZ+mVNB arm, induced high expression of
immune-related genes and gene signatures such as the
Tumor Inflammation Signature (TIS) [29], the CD8 T cell
signature, macrophages, and immune checkpoint inhibitors
PDL1 and PDL2. Most of these changes in gene and gene
signature expression were not identified in the mVNB-only
arm, except for the high expression of the inflammatory che-
mokine signature (Figs. 4 and 5a). Compared to the other
arms, the mVNB monotherapy induced a more differentiated
luminal phenotype with increased expression of ESR1, estro-
gen-regulated gene signature, and FOXA1 (Fig. 5a).
Immune infiltration
The previous results suggested that immune infiltra-
tion was enriched in post-treatment samples of the
LTZ-containing arms, especially the combination arm.
To further evaluate this, we identified the presence of
sTILs before and after treatment. Overall, ≥ 10% of
sTILs at 3 weeks were observed in 6.6% (1/15), 15% (2/
20), and 26% (5/19) of the cases within the mVNB-
only, LTZ-only, and combination arms, respectively
(Additional file 3: Figure S2A). In tumors with ≤ 10%
sTILs at baseline, a statistically significant increase in
sTILs was observed following LTZ (p = 0.049) and
VNB+LTZ (p = 0.012), but not in the mVNB-only arm
(Additional file 3: Figure S2B). Thus, this pathology-
based analysis confirms the previous gene signature-
based results.
Global gene expression changes
In this study, the expression of 752 genes and 32 breast
cancer-related gene signatures were analyzed at both
time points. Thus, we explored the changes in the ex-
pression of each individual gene in each treatment arm.
After adjusting for multiple testing (FDR < 5%), the
number of genes whose expression significantly changed
in each arm was 410 (52.3%) in the LTZ+mVNB arm,
401 (51.2%) in the LTZ-only arm, and 29 (3.7%) in the
mVNB-only arm (Fig. 5c and Additional file 4). As ex-
pected, a considerable overlap of genes (60%) occurred
between both LTZ-containing arms (Fig. 5c).
Fig. 1 Flow chart of the SOLTI-1501 VENTANA study
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Compared to the baseline samples, post-treatment
samples in the combination arm showed higher ex-
pression of AP-1 transcription factor subunits FOS
and JUN, inflammatory chemokines (e.g., CCL4, IL6,
and CCL3L1), and stromal-related genes (e.g., CAV1).
Concordant with this observation, the upregulated
gene list in the post-treatment time point was found
enriched with the following biological processes: in-
flammatory response, chemokine-mediated signaling
pathway, chemotaxis, and adaptive immunity. On the
contrary, post-treatment samples in the combination
arm showed lower expression of cell cycle-related
genes (e.g., AURKA and UBE2C), DNA repair (e.g.,
BRCA1, BRCA2 and RAD51), and microtubule (e.g.,
MAPT and KIF11).
Of the 410 genes found differentially expressed in the
combination arm, 107 (26.1%) were not found in the
LTZ-only differentially expressed gene list (Fig. 5c and
Additional file 4). Within this gene list, 78 and 29 genes
were upregulated and downregulated in post-treatment
samples, respectively. Within the upregulated gene list,
we identified the immune checkpoint inhibitor LAG3
and immune-related genes such as IL1B, CCR5, and
CXCL8 (Additional file 4). Within the downregulated
gene list, we identified the ESR1 and the prolifera-
tion-related genes CHEK2 and FANCF and others
such as MTOR. From both gene lists, no significant
enrichment for any particular biological process was
identified.
In the LTZ-only arm, 98 (24.4%) differentially expressed
genes were not found in the combination arm. Within this
gene list, 91 and 7 genes were upregulated and down-
regulated in post-treatment samples, respectively (Fig. 5c and
Additional file 4). However, no significant enrichment for
any particular biological process was identified from both
gene lists.
Fig. 2 Distribution of the intrinsic subtypes before (a, c, e) and after treatment (b, d, f) in LTZ (a, b), mVNB-only (c, d), and combination
(e and f) arms
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Evaluation of the chemo-endocrine score
We have previously reported a PAM50-based chemo-
endocrine score (CES) in HR+/HER2− early disease
that predicts response to endocrine therapy vs.
chemotherapy [30]. Here, we explored the association
of CES (as a continuous variable and using the previ-
ously established cutoffs) with the biological response,
measured as > 50% relative decrease in the 11-gene
proliferation signature. In the LTZ-only arm, the re-
sponse in the CES-high (high endocrine sensitive and
low chemo-sensitive) and CES-med (low endocrine
sensitive and high chemo-sensitive) groups was 72.7%
(8/11) and 37.5% (3/8) of the patients, respectively. Of
note, only one CES-low sample was identified in the
LTZ-only arm. In the mVNB-containing arms, the
response in the CES-high, CES-med, and CES-low
groups was 50% (9/18), 45% (5/11), and 80% (4/5) of
the patients, respectively. The interaction between
CES (as a continuous variable) and treatment (LTZ vs.
mVNB) was statistically significant (p = 0.039).
Discussion
Prior studies have evaluated and studied the combination
of vinorelbine and endocrine therapy. In the preclinical set-
ting, synergistic activity between vinorelbine and hormone
therapy has been observed [16]. In the clinical setting, a
single-arm phase II clinical trial combining vinorelbine and
tamoxifen in 38 evaluable patients as the first-line therapy,
of whom 63% had positive and 29% unknown hormonal re-
ceptor status, the overall response rate was 66% and the
complete response rate was 16%. No evidence of additive
side effects was observed. Another single-arm clinical trial
tested LTZ in combination with vinorelbine in postmeno-
pausal women with metastatic breast cancer. This combin-
ation appeared to be an active regimen (overall response
rate of 50%) with a favorable safety profile [31]. Interest-
ingly, a phase III trial in patients with hormone-refractory
prostate cancer, progression-free survival (PFS) was
significantly prolonged when vinorelbine was combined
with hormone therapy compared with hormone therapy
alone [32].
From a biological perspective, the secondary and ex-
ploratory results of the VENTANA trial suggest that
adding mVNB to LTZ might lead to the expression of
specific biological features. Several observations support
this hypothesis. On one hand, according to gene expres-
sion data, mVNB monotherapy induces a biological pro-
file consistent with high endocrine dependency, with
upregulation of ESR1, FOXA1, and the ER-regulated
gene signature and downregulation of the 11-gene pro-
liferation signature. On the other hand, although the
two LTZ-containing arms show a very similar biological
profile after treatment, the LTZ+mVNB arm has a more
Fig. 3 Relative reduction of PAM50 proliferation score in Luminal A/B disease. a The 11-gene proliferative score at baseline vs. surgery. b Changes
in the proliferation score in each arm. c Primary results of the study: On the left, the anti-proliferative effect of the combination of mVNB and LTZ
vs. both monotherapy arms combined. On the right, comparison of the anti-proliferative effect between each treatment arm. Error bars indicate
95% confidence interval
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pronounced and consistent upregulation of immune-re-
lated genes and gene signatures, an increase in sTILs,
and a more pronounced and consistent downregulation
of proliferation and cell-cycle-related genes. Thus, it is
plausible that mVNB has the ability to differentiate the
tumor cells into a slightly more estrogen-dependent
state, and in this context, LTZ is more effective. Further
studies are needed to confirm this hypothesis. However,
other treatments that inhibit the cell cycle such as PI3K
inhibitors have shown to increase estrogen dependency
of the tumor cell in the preclinical setting [33]. Another
hypothesis is that mVNR affects cells within a tumor
with the highest proliferation, leaving untreated those
that are not sensitive to chemotherapy but are likely
highly sensitive to letrozole.
A low proliferation in response to preoperative endocrine
therapy predicts for a good long-term outcome, whereas high
levels have been associated with an increased risk of breast
cancer recurrence [34]. In our study, the anti-proliferative ef-
fect arm in luminal tumors of the combination of mVNB
and LTZ was superior than that in the monotherapy arms.
Ki67 detected by immunohistochemistry is currently the
most used marker to estimate tumor cell proliferation. The
Ki67 score measured at 2weeks in IMPACT [35], at 16
weeks in P024 [36], and at 2 to 4weeks in ACOSOG Z1031
[37] was predictive of relapse-free survival in multivariate
analysis, whereas the pretreatment Ki67 was not. Utilizing
the long-term outcomes of the patients from P024, Ellis et al.
found that pathologic stage (tumor size and nodal status), in
addition to the levels of the protein Ki67, and Allred ER
Fig. 4 Biological changes induced by each treatment at week 3 compared to baseline of selected genes and gene signatures
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score measured on the surgical specimen were independently
associated with both relapse-free survival and breast cancer-
specific survival [38]. The preoperative endocrine prognostic
index (PEPI score) was developed based on these findings
and validated in the outcome data from the IMPACT and
ACOSOG Z1031 trials. The ongoing randomized phase III
ALTERNATE clinical trial (NCT01953588) in women with
HR+/HER2− early breast cancer is testing a biomarker-
driven treatment strategy based on Ki67 values following 4
and 12weeks of neoadjuvant hormonotherapy and the PEPI
score to identify women at low risk of disease recurrence.
HR+/HER2− breast cancer is generally considered non-im-
munogenic [39, 40]. In agreement with previous studies, only
9.3% (5/54) of tumor samples in our study showed > 5% of
stromal sTILs. However, an interesting result is the increase
in immune-related genes and signatures after 3 weeks of
treatment in both LTZ-containing arms, especially with the
LTZ+mVNB combination. This observation is consistent
with prior studies. For example, 6months of letrozole alone
or in combination with metronomic cyclophosphamide was
able to reduce the presence of intra-tumoral FOXP3+ Tregs
in 83 elderly breast cancer patients [41]. In another study, an
increased expression of genes related to inflammatory pro-
cesses, with enrichment of those promoting T cell anergy,
was observed after 3months in responders to neoadjuvant
anastrozole [42]. The immune effects of anastrozole have
Fig. 5 Global gene expression changes induced by each arm from baseline to surgery. a Heatmaps showing differential expression of 49 selected
genes and gene signatures at 3 weeks in each arm. b 360° view summarizing the gene/signatures for the breast tumor microenvironment and
immune response in LTZ+mVNB arm between baseline and surgery. c Venn diagram showing the overlap in the list of differentially expressed
genes obtained in the before and after treatment across the comparisons of the three arms
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also been described in rat models, with increased levels of
proinflammatory cytokines and suppression of Treg differen-
tiation induced by this drug. A combination approach with
pembrolizumab, an anti-PD1 antibody, in association with
anastrozole, exemestane, or letrozole (in the ER-positive
cohort of the study) is being evaluated in patients with ER-
positive metastatic breast cancer (NCT02648477), and
neoadjuvant durvalumab, an anti-PDL1 antibody, is being
explored in a phase II trial (ULTIMATE, NCT02997995) in
combination with exemestane in patients whose tumor is
found inflamed (i.e., > 10% CD8+ T cells) after 3weeks of
exemestane with tremelimumab, an anti-CTLA4 antibody.
Metronomic chemotherapy schedule seems to have
not only a direct cytotoxicity on cancer cells but also an
effect on the tumor microenvironment by modulating
immune response [43–47]. However, in our study, the
mVNR alone did not increase immune metrics as much
as letrozole in monotherapy. On one hand, the dose of
mVNR might be too low to induce this effect. On the
other hand, the duration of mVNR might be too short.
Indeed, studies with metronomic schedules that support
the effect on the immune system have a longer duration.
The randomized design of this window of oppor-
tunity trial allowed us to explore the ability of our
previously described PAM50-based CES signature to
predict response to chemotherapy vs. endocrine ther-
apy. As expected, CES showed the inverse pattern of
association as previously reported, where high CES
values are associated with endocrine sensitivity and
chemo-resistance and the low values are associated
with endocrine resistance and chemo-sensitivity.
Despite the low number of patients in each arm, the
interaction test between CES and treatment for their
association with a response was statistically signifi-
cant. This result gives us a strong rationale to test, in
an upcoming collaboration, the predictive value of
CES to adjuvant chemotherapy in the Danish Breast
Cancer Cooperative Group 77B clinical trial, which
randomized 1072 premenopausal women to no sys-
tematic treatment (control), levamisole, cyclophospha-
mide, or cyclophosphamide-methotrexate-fluorouracil
arms [48, 49].
Our study has limitations worth noting. First, the sample
size chosen was not based on a formal statistical assump-
tion since no prior window study had evaluated this com-
bination and this biomarker (i.e., 11-gene proliferation
signature). We do note, however, that the observed magni-
tude of difference in our study for the primary objective
(i.e., 23.3%) and the given sample size has a statistical power
of 83.6%. Considering the meaning of a post hoc analysis as
a prospective measure, this power means that a new trial
testing the same hypothesis with the same sample size and
biomarker will have a probability of 83.6% of ending up
with a p value of less than 5%. Second, whether longer
duration of treatment might induce different results is un-
known. Third, no claims regarding clinical benefit can be
made. However, our results suggest that adding endocrine
therapy in patients with advanced HR+/HER2− disease that
is treated with mVNB might not be detrimental and might
actually be of potential benefit. The results of a prior study
support this hypothesis. Bottini and colleagues [50] com-
pleted a neoadjuvant randomized phase II trial where they
combined letrozole with low-dose oral cyclophosphamide
for 6 months. The investigators observed an overall
response rate of 71.9% in the 57 patients randomly
assigned to receive primary letrozole and 87.7% in the
57 patients randomly assigned to receive letrozole
plus cyclophosphamide. In addition, there was a
significantly greater suppression of Ki67 expression in the
letrozole/cyclophosphamide-treated group than in the
letrozole-treated group. Fourth, we focused our molecular
analysis on a set of 752 genes and 32 gene signatures.
Whether other biological processes might be occurring
and are being missed by our study is unknown.
Conclusions
To conclude, short-term mVNB in combination with
LTZ presents high anti-proliferative activity and is well-
tolerated compared to monotherapy. However, anti-pro-
liferative activity does not seem to be higher than LTZ
alone. Further investigation comparing these biological
results with other metronomic schedules or drug combi-
nations is warranted. In particular, the high expression
of immune-related biological processes and sTILs
observed with the combination opens the possibility of
studying this combination with immunotherapy. Further
investigation comparing these biological results with
other metronomic schedules or drug combinations is
warranted.
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